OBJECTIVES: To clarify policies regarding management of HIV-infected women, relating to pregnancy, in view of current European consensus guidelines. STUDY DESIGN: Postal questionnaire survey in 36 hospitals in 11 European countries. RESULTS: Responses were received from 22 (61%) centres, representing all 11 countries. In principle, antiretroviral therapy (ART) would be reviewed in treated women wanting to become pregnant in nearly all centres. Multidisciplinary management of infected pregnant women was routine in 17 (77%) centres, facilitating continuity of care. Approximately half the clinicians would use zidovudine monotherapy for pregnant women without indications for ART, while the remainder prescribed combination therapy. In 1998-2000, pre-eclampsia was the most prominent adverse event (22 centres) in women receiving ART, with congenital abnormalities (13 abnormalities in 6 centres) and stillbirth (5 centres) also reported. CONCLUSIONS: Policies varied, particularly regarding prophylactic ART for women without indications for treatment and did not always follow current European guidelines.
OBJECTIVES: To clarify policies regarding management of HIV-infectedwomen, relating to pregnancy, in view of current European consensus guidelines. STUDY DESIGN: Postal questionnaire survey in 36 hospitals in 11 European countries. RESULTS: Responses were received from 22 (61%) centres, representing all 11 countries. In principle, antiretroviral therapy (ART) would be reviewed in treated women wanting to become pregnant in nearly all centres. Multidisciplinary management of infected pregnant women was routine in 17 (77%) centres, facilitating continuity of care. Approximately half the clinicians would use zidovudine monotherapy for pregnant women without indications for ART, while the remainder prescribed combination therapy. In 1998-2000, pre-eclampsia was the most prominent adverse event (22 centres) in women receiving ART, with congenital abnormalities (13 abnormalities in 6 centres) and stillbirth (5 centres) also reported. CONCLUSIONS: Policies varied, particularly regarding prophylactic ART for women without indications for treatment and did not always follow current European guidelines.
Authors: Marie C D Stoner; Bellington Vwalika; Marcela C Smid; Shalin George; Benjamin H Chi; Elizabeth M Stringer; Jeffrey S A Stringer Journal: Int J Gynaecol Obstet Date: 2016-05-25 Impact factor: 3.561
Authors: M Floridia; M Ravizza; E Tamburrini; G Anzidei; C Tibaldi; A Maccabruni; G Guaraldi; S Alberico; A Vimercati; A Degli Antoni; E Ferrazzi Journal: Epidemiol Infect Date: 2006-03-02 Impact factor: 2.451
Authors: Marie-Louise Newell; Sharon Huang; Simona Fiore; Claire Thorne; Laurent Mandelbrot; John L Sullivan; Robert Maupin; Isaac Delke; D Heather Watts; Richard D Gelber; Coleen K Cunningham Journal: BMC Infect Dis Date: 2007-06-20 Impact factor: 3.090